ストックスクリーナーアプリを入手
290.07
0.19%
-0.5127
前日終値:
$290.58
開ける：
$293.3
24時間の取引高:
101.15K
Relative Volume:
0.42
時価総額：
$30.11B
収益：
$5.76B
当期純損益:
$514.49M
株価収益率:
64.73
EPS:
4.4813
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
-6.52%
1か月 パフォーマンス:
-0.27%
6か月 パフォーマンス:
-14.85%
1年 パフォーマンス:
+17.57%
1日の値動き範囲:
$288.36
$294.30
1週間の範囲:
$288.34
$312.01
52週間の値動き範囲:
$239.25
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
名前
Beone Medicines Ltd Adr
セクター
電話
41-616851900
住所
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
290.21 | 30.15B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
446.66 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.87 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
834.10 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.35 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.71 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | 開始されました | Wolfe Research | Outperform |
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-09-18 | 開始されました | Barclays | Overweight |
| 2025-04-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-03 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-12-03 | 再開されました | Morgan Stanley | Overweight |
| 2024-09-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-06 | 再開されました | JP Morgan | Overweight |
| 2023-09-12 | 開始されました | Macquarie | Outperform |
| 2023-08-17 | 開始されました | Jefferies | Buy |
| 2023-07-17 | 開始されました | Citigroup | Buy |
| 2023-06-30 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 開始されました | Daiwa Securities | Buy |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-10-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 再開されました | JP Morgan | Overweight |
| 2022-03-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 開始されました | Deutsche Bank | Buy |
| 2021-10-12 | 開始されました | Bernstein | Outperform |
| 2021-10-06 | アップグレード | CLSA | Underperform → Buy |
| 2021-03-08 | 開始されました | China Renaissance | Buy |
| 2021-03-01 | ダウングレード | CLSA | Outperform → Underperform |
| 2020-11-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-06 | ダウングレード | Piper Sandler | Neutral → Underweight |
すべてを表示
Beone Medicines Ltd Adr (ONC) 最新ニュース
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma - Sahm
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer - Sahm
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Apple Upgraded, American Express Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer - Sahm
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Guggenheim raises BeOne Medicines stock price target to $420 By Investing.com - Investing.com India
BOCI: BEONE MEDICINES 1Q Results Beat; Rating Buy Reiterated - AASTOCKS.com
G Sachs Raises BeOne Medicines Ltd. (ONC.US) TP to USD414.46, Rating Buy - AASTOCKS.com
UBS Raises BeOne Medicines Ltd. (ONC.US) TP to USD465, 1Q Results Strong - AASTOCKS.com
M Stanley Raises BeOne Medicines Ltd. (ONC.US) TP to USD395; 1Q Results Beat Expectations - AASTOCKS.com
BeOne Medicines Q1 Earnings Call Highlights - Yahoo Finance
BeOne Medicines (ONC) registers 398.9M ordinary shares for resale by major holders - Stock Titan
BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance - AASTOCKS.com
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates - STT Info
Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain? - Sahm
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BeOne Medicines files 2025 annual report with Shanghai STAR Market - Investing.com
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Is BeOne (ONC) Stock entering maturity stage | ONC Q4 2025 Earnings: BeOne Medicines Ltd. ADS misses EPS, no revenue releasedADR - Newser
RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating - Moomoo
A Look At BeOne Medicines (ONC) Valuation After New Coverage And FDA Orphan Drug Designation - Sahm
BeOne Medicines (NASDAQ:ONC) Stock Price Down 6.2%Here's Why - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s Why - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00 - Defense World
Jain Global LLC Sells 32,244 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Beone Medicines Ltd Adr (ONC) 財務データ
収益
当期純利益
現金流量
EPS
1.07%
大文字化:
|
ボリューム (24 時間):